C R Bard Inc (BCR) : Gvo Asset Management Ltd added new position in C R Bard Inc during the most recent quarter end. The investment management firm now holds 11,985 shares of C R Bard Inc which is valued at $2,779,202 , the company said in a statement filed on Jul 14, 2016 with the SEC.C R Bard Inc makes up approximately 0.31% of Gvo Asset Management Ltd’s portfolio.
Other Hedge Funds, Including , Chevy Chase Trust Holdings boosted its stake in BCR in the latest quarter, The investment management firm added 419 additional shares and now holds a total of 63,194 shares of C R Bard Inc which is valued at $15,103,366. C R Bard Inc makes up approx 0.08% of Chevy Chase Trust Holdings’s portfolio.Ct Mason reduced its stake in BCR by selling 528 shares or 2.34% in the most recent quarter. The Hedge Fund company now holds 22,049 shares of BCR which is valued at $5,269,711. C R Bard Inc makes up approx 2.20% of Ct Mason’s portfolio.
C R Bard Inc closed down -0.34 points or -0.15% at $231.89 with 2,39,254 shares getting traded on Monday. Post opening the session at $232.78, the shares hit an intraday low of $231.06 and an intraday high of $233.7046 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016. Company shares were Reiterated by Barclays on May 24, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 224 from a previous price target of $212 .Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.